Defining Translational Approaches for the Image-based Detection of Prenatal Alcohol Exposure

作为CIFASD 5的一个组成部分，该项目将侧重于改进 产前酒精暴露（PAE）的个体，在整个生命周期中，主要目标是 临床应用的翻译。我们的目标是申请表中列出的两个主要类别 (RFA)1.一、早期准确识别FASD病例;扩展和翻译基本和 对PAE影响的机械理解。为了解决这些问题，我们的目标是改善 FASD临床识别的准确性和可靠性，控制性别、共同 暴露和年龄。我们试图更好地理解神经认知和面部形态是如何 FASD中的相关性和协变性，并利用这种关系来提高筛选精度。 以前，我们已经实现了用于分析脸部形状和脸部的方法和相关软件， 大脑认知关系来检测PAE的影响。在这样做的过程中，我们创造了一个有效的 自动客观识别主要和微妙PAE相关面部畸形的工具包 在FASD范围内。现在的首要任务是改进和优化我们的方法，利用低成本 3D成像设备进行验证并分发给临床社区。为了实现目标，我们 建议实现以下具体目标： 1.探讨酒精暴露后可能影响面部形态的因素的影响; 2.检测胎儿期酒精暴露对面部、颅骨和神经的影响; 3.开发、测试和验证FASD筛查的自动化方法， 评估工具并分发给临床社区。 实现目标1和目标2将通过了解这些因素， 继发于酒精，可能会影响整个生命周期的结果。成功演示 目标2将实现尽可能早的诊断，以便进一步研究和反馈， 干预研究，也专注于识别成年人的特征-一个人口显着 在文献中被低估了。最终，目标3包含了项目的主要目标， 开发，测试和验证多域筛选工具，以帮助临床识别。 我们将与联盟伙伴密切合作，他们将招募受试者并提供面部图像， 神经认知评估数据（U 01：Chambers; U 01：Coles &温伯格; U 01：Wozniak; U 01： DiClemente; U01：Petrenko）.特别是面部神经认知需要密切合作 分析，我们将整合和联合收割机面部和神经认知筛查工具（U 01： Mattson）。我们将依靠研究资源进行数据管理（R24：Wetherill），并验证 筛选工具并获得临床反馈（R24：Del Campo）。

As a constituent component of CIFASD5, this project will focus on improving the identification of individuals with prenatal alcohol exposure (PAE), across the lifespan, with the primary goal of translation for clinical application. We target two main categories outlined in the Request for Application (RFA) 1. To identify FASD cases early and accurately, and 2. To expand and translate basic and mechanistic understandings of the effects of PAE. To address these topics, we aim to improve the accuracy and reliability of the clinical recognition of FASD, controlling for the influence of sex, co- exposures, and age. We seek to understand better how neurocognitive and facial morphology are correlative and covariant in FASD and exploit this relationship to improve screening accuracy. Previously, we have implemented methods and associated software for analyzing face shape and face - brain-cognitive relationships to detect the effects of PAE. In doing so, we have created an effective toolkit to automatically and objectively identify cardinal and subtle PAE-associated facial dysmorphism across the FASD spectrum. It is now a priority to refine and optimize our methods, utilizing low-cost 3D imaging devices to validate and distribute to the clinical community. To accomplish our goals, we propose to follow specific aims: 1. Explore the impact of factors secondary to alcohol exposure that may influence facial morphology; 2. Detect facial, cranial, and neural effects of prenatal alcohol exposure across the lifespan; 3. Develop, test, and validate automated methods for FASD screening, integrating neurocognitive assessment tools and distributing to the clinical community. Achieving aims 1 and 2 will dramatically refine FASD recognition by understanding the factors secondary to alcohol that may influence outcomes across the lifespan. Successful demonstration of aim 2 will achieve the earliest possible diagnosis enabling further research and feedback for intervention studies and also focus on recognizing traits in adults - a population significantly underreported in the literature. Ultimately, aim 3 encompasses the primary goal of the project, developing, testing, and validating multi-domain screening tools that assist with clinical identification. We will work closely with consortium partners who will recruit subjects and provide facial images and neurocognitive assessment data (U01: Chambers; U01: Coles & Weinberg; U01: Wozniak; U01: DiClemente; U01: Petrenko). Particularly close collaboration is required for the face-neurocognitive analysis, where we will integrate and combine facial and neurocognitive screening tools (U01: Mattson). We will rely on research resources for data management (R24: Wetherill) and to validate screening tools and gain clinical feedback (R24: Del Campo).